Related Experiment Video
Updated: Sep 10, 2025

Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method
Published on: April 18, 2019
New Perspectives on Antimicrobial Agents: Sulbactam-durlobactam
Jason M Pogue1,2, Jeffrey Harrington1,2, Walaiporn Wangchinda3
1Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, Michigan, USA.
Abstract:
Infections due to Carbapenem-resistant Acinetobacter baumannii (CRAB) are a significant burden and are associated with devastating outcomes. Subsequently, CRAB is recognized as an urgent threat to human health by the United States (US) Centers for Disease Control and Prevention and is designated a critical pathogen, with the highest priority for research and development of novel treatment options, by the World Health Organization. Sulbactam-durlobactam was approved by the US Food and Drug Administration in 2023 for the treatment of Hospital Acquired and Ventilator Associated Bacterial Pneumonia caused by susceptible strains of A. baumannii, and as of 2024, is the Infectious Diseases Society of America Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections preferred treatment strategy, in combination with a carbapenem, for infections due to CRAB. In this commentary, we will dive into the preclinical and clinical evidence supporting this approval. We will further explore controversial and emerging questions related to sulbactam-durlobactam, including the necessity of carbapenem combination therapy for CRAB and the other potential therapeutic opportunities durlobactam may provide beyond A. baumannii.
More Related Videos
11:15Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations
Published on: July 24, 2021
11:28A Reference Broth Microdilution Method for Dalbavancin In Vitro Susceptibility Testing of Bacteria that Grow Aerobically
Published on: September 9, 2015
Related Concept Videos
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Antimicrobial Effectiveness
Oral Hypoglycemic Agents: Sulfonylureas
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Development of Antibiotic Resistance
Acute Pyelonephritis II: Diagnostic Studies and Management